FluoGuide is a clinical stage biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent.
New exchange: Nasdaq First North
FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.
November 24, 2022
Press release
FluoGuide A/S publishes interim report for the period January – September 2022
7-9 January 2023
Presentation on SEB Nordic Seminar
22 February 2023
Life Science Investor Konference | Økonomisk Ugebrev
28 February 2023
24 November 2022
Presentation at Redeye Life Science Day 2022
FluoGuide develops drugs for maximizing surgical outcomes by making cancer fluorescent. Our lead product candidate makes solid cancers light up during surgery and has proven to be safe and well-tolerated in patients. Successful application of FluoGuide’s products will lower system-wide healthcare costs because it will reduce the recurrence of cancer and lessen general surgical complications. Thereby, patients will require fewer readmissions to hospitals. Ultimately, these improvements will improve patients’ chances of achieving a complete cure.
FluoGuide’s pipeline consists of product candidates that can potentially make most solid cancers fluorescent. We advance our pipeline at a rapid pace for the benefit of patients with cancer, society, and our shareholders. FluoGuide’s lead-product, FG001, is in phase IIa clinical development targeting patients undergoing surgical removal of high-grade glioma. FluoGuide is also developing FG001 in lung cancer and Head & Neck cancer. Pre-clinical development has been initiated for an additional drug, FG002. Both drug candidates utilize FluoGuide’s proprietary uPAR technology platform.
